Business, energy, technology, markets and global industry news from Business News Today

nipocalimab

PharmaDeviceNews nipocalimab
Pharma & Biotech

Can IMAAVY’s sustained control data reshape earlier treatment of generalized myasthenia gravis?

Discover what Johnson & Johnson’s new IMAAVY data mean for earlier gMG treatment, sustained control, safety and FcRn competition.

Read More
A hematology specialist reviews red blood cell findings as Johnson & Johnson advances nipocalimab as a potential first targeted treatment for warm autoimmune hemolytic anemia. Representative image.
Pharma & Biotech

Johnson & Johnson strengthens nipocalimab’s FDA case with rapid hemoglobin improvement

The ENERGY trial strengthens the regulatory case for nipocalimab in warm autoimmune hemolytic anemia, but modest response rates and long-term IgG suppression remain important questions.

Read More
Representative image of immunology research and clinical trial analysis, reflecting Johnson & Johnson’s growing nipocalimab strategy in lupus and Sjögren’s disease.
Pharma & Biotech

Why Johnson & Johnson’s lupus and Sjögren’s data matter beyond one Phase 2 readout

See how Johnson & Johnson’s nipocalimab data could reshape lupus and Sjögren’s disease treatment strategy today!

Read More